Endometriosis and Microvascular Dysfunction: Role of Inflammation

This study is looking into how endometriosis might increase the risk of heart and blood vessel problems, and if a medication called Salsalate can help. Researchers want to understand the link between endometriosis, inflammation, and heart disease risk. You might be able to join if you are a woman between 18 and 45 years old, either healthy or diagnosed with endometriosis within the last 5 years. Participants will receive either Salsalate pills, which aim to reduce inflammation, or a placebo (an inactive pill). The study will measure changes in blood vessel function and a protein called LOX-1 to see if Salsalate is effective. The study plans to enroll 24 participants, but its current status is unclear.

Study design: This is an interventional study planning to enroll 24 women. Participants will receive either Salsalate or a placebo.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: Measurements will be taken 5 days after treatment to assess changes in blood vessel function and protein levels.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Endometriosis and Microvascular Dysfunction: Role of Inflammation

Recruiting

EARLY_PHASE1Ages 18–45InterventionalBasic science

Penn State University

~24 participants

Updated 2026-07-27 on ClinicalTrials.gov

What's tested:Salsalate PillPlacebo

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

cutaneous vascular conductance

Measured over 5 days after treatment

+3 more outcomes measured

Conditions

Endometriosis

Where it's being run

1 sites across 1 states

Pennsylvania1

Who to contact

Lacy M Alexander, Ph.D.

[email protected]

8148671781

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Healthy women between the ages of 18 and 45 years (Controls), taking oral contraceptive or with regular menses every 26-34 days

Women between the ages of 18 and 45 years with endometriosis (diagnosis by prior laparoscopy by subject's own physician \<5 years prior, and reported by the subject to the researchers)

Tylenol if the subject has acute pain is allowed

Contraceptive use is allowed

Exclusion

Use of nicotine-containing products (e.g. smoking, chewing tobacco, etc.)

Diabetes (HbA1C 6.5%)

BP\>140/90

Taking pharmacotherapy that could alter peripheral vascular control (e.g. insulin sensitizing, cardiovascular medications)

Pregnancy

Breastfeeding

Taking illicit and/or recreational drugs

Abnormal liver function

Rash, skin disease, disorders of pigmentation, known skin allergies

Diagnosed or suspected metabolic or cardiovascular disease

Persistent unexplained elevations of serum transaminases

Known allergy to latex or investigative substances (including salsalate or simvastatin)

History of gastrointestinal bleeding

What this trial measures

cutaneous vascular conductance5 days after treatment
doppler flowmetry used to measure cutaneous vascular conductance (cvc = red cell flux/mean arterial pressure) to assess microvascular endothelial function
brachial artery diameter and blood flow velocity5 days after treatment
continuous ultrasound imaging measurements of brachial artery diameter and blood flow velocity to assess endothelial function
Sera LOX-1 protein expression5 days after treatment
Peripheral Blood Mononuclear Cell Isolation, LOX-1 expression quantified using real time pCR
Biopsy LOX-1 protein expression5 days after treatment
Bio-Rad DC assay, western blot technique used for LOX-1 protein receptor expression

Trialytics